• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ImmunoGen initiates phase I trial in non-Hodgkin's lymphoma

ImmunoGen initiates phase I trial in non-Hodgkin's lymphoma

April 18, 2012
CenterWatch Staff

ImmunoGen, a biotechnology company that develops anticancer therapeutics using Targeted Antibody Payload (TAP) technology, has begun a phase I trial of its IMGN529 anticancer compound.

The phase I trial will evaluate the safety, tolerability, pharmacokinetic profile and anticancer activity of escalating doses of IMGN529 in 55 patients with relapsed or relapsed/refractory, CD37-expressing non-Hodgkin's lymphoma (NHL) to establish the dose for future clinical trials. NHL is typically treated with the anticancer antibody, rituximab and chemotherapy. IMGN529, a TAP compound, contains a B-cell-targeting antibody that has demonstrated marked anticancer activity in preclinical testing. Attached to this antibody is a potent ImmunoGen cell-killing agent, DM1. The antibody serves to kill the cancer cells through multiple antibody-mediated mechanisms and also deliver the DM1 specifically to the cancer cells for additional, targeted anticancer potency.

"The phase I trial now underway, together with our market research, is expected to provide the information needed to define a clear development path for IMGN529 in NHL," said James O'Leary, MD, vice president and CMO. "With its unique profile, we believe IMGN529 has the potential to be an important new therapy for the treatment of key B-cell malignancies."

Patients with follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, or marginal zone lymphoma—the more common types of NHL—are still eligible for enrollment.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing